Yasir A Skeiky

This inventor holds 34 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Infectious Disease Vaccines. Top assignees: Corixa Corporation, Glaxosmithkline Biologicals Sa. Active years: 1998-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasir A Skeiky. Retrieved from https://idiyas.com/inventor/yasir-a-skeiky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 34 (Patent Applications = 4)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.4

ph-index = 15

Forward Citations = 436(Granted Patents)

Location History:

King, WA (US) (1998)
Seattle, WA (US) (1999 - 2011)
Bellevue, WA (US) (2003 - 2012)
Silver Spring, MD (US) (2013)

Company Filing History:

Glaxosmithkline Biologicals Sa

patents

where one patent can have more than one assignee

Years Active: 1998-2013

Loading Chart...

Areas of Expertise:

Vaccines

Chlamydial Infection

Tuberculosis

Fusion Proteins

Immunotherapy

Diagnostics

Leishmaniasis

T. Cruzi

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8541007 - Vaccines against chlamydial infection (2013-09-24),

2. 8143386 - [object Object] (2012-03-27),

3. 8110201 - Fusion proteins of mycobacterium tuberculosis (2012-02-07),

4. 8110200 - [object Object] (2012-02-07),

5. 8071747 - Fusion proteins of mycobacterium tuberculosis (2011-12-06),

6. 8067016 - [object Object] (2011-11-29),

7. 7982025 - [object Object] (2011-07-19),

8. 7976844 - [object Object] (2011-07-12),

9. 7973153 - Fusion proteins of mycobacterium tuberculosis (2011-07-05),

10. 7935353 - Compounds and methods for diagnosis and immunotherapy of tuberculosis (2011-05-03),

11. 7927611 - Compounds and methods for diagnosis and immunotherapy of tuberculosis (2011-04-19),

12. 7927610 - Compounds and methods for diagnosis and immunotherapy of tuberculosis (2011-04-19),

13. 7691993 - [object Object] (2010-04-06),

14. 7678375 - [object Object] (2010-03-16),

15. 7335369 - [object Object] (2008-02-26),

Title: Yasir A Skeiky: A Pioneer in Vaccine Innovations

Introduction

Yasir A Skeiky, based in Bellevue, WA, is a prominent inventor in the field of immunology, holding an impressive portfolio of 34 patents. His contributions are significant, particularly in the development of vaccines aimed at combating various infections, showcasing his dedication to advancing medical science.

Latest Patents

Among his latest patents, Yasir has developed groundbreaking vaccines against chlamydial infection. His invention pertains to compositions comprising proteins or polynucleotides that play a crucial role in the treatment, prevention, and diagnosis of these infections. Additionally, he has worked on innovative fusion proteins that include various antigens. This includes bi-fusion, tri-fusion, tetra-fusion, and penta-fusion proteins, which are aimed at addressing tuberculosis infection, providing new avenues for diagnosis and treatment.

Career Highlights

Yasir A Skeiky has had an illustrious career, contributing to significant advancements in vaccine technology. He has been affiliated with notable organizations such as Corixa Corporation and GlaxoSmithKline Biologicals SA. His work in these companies has positioned him as a key figure in the vaccine research community.

Collaborations

Throughout his career, Yasir has collaborated with esteemed professionals in the field, including Steven G Reed and Mark R Alderson. These collaborations have fostered an environment of innovation, merging expertise from various domains to tackle complex medical challenges.

Conclusion

Yasir A Skeiky's work continues to impact the field of vaccine development significantly. His patents reflect his innovative spirit and commitment to improving public health through targeted and effective medical interventions. As he progresses in his career, the scientific community eagerly awaits his future contributions and advancements.

Profile summary based on public USPTO records.